α-干扰素联合苦参素治疗对肝功能和肝纤维化指标的影响

目的:观察α-干扰素(IFN-α)联合苦参素治疗对慢性乙型肝炎患者肝功能和肝纤维化指标的影响。方法:将慢性乙肝患者100例,随机分为治疗组52例,对照组48例。治疗组采用IFN-α5 Mu/d,肌注,q.d,连用2周后改隔日1次,疗程6月。同时加用苦参素注射液600 mg/d,q.d,静滴,3月后改口服苦参素胶囊,300 mg,t.i.d,疗程共6月。对照组则单用IFN-α,剂量疗程相同。疗程结束时,观察两组患者肝功能及血清肝纤维化等指标变化。结果:IFN-α联合苦参素治疗组丙氨酸转氨酶复常率为80.77%,两组比较差异有显著性(P<0.05):治疗组血清透明质酸、层粘蛋白、Ⅲ型前胶原、Ⅳ型胶原等指标与对照组比较均具有显著性差异(P<0.05或P<0.01)。结论:IFN-α联合苦参素治疗具有改善肝功能和抗肝纤维化等疗效。

Effect of Interferon Alpha Combined with Oxymatrine on Liver Function and Fibrosis in Patients with Chronic Hepatitis B

Objective:To study the effect of interferon alpha(IFN-α) combined with oxymatrine on liver function and fibrosis in treating chronic hepatitis B.Methods:100 patients with chronic hepatitis B were randomly divided into oxymatrine with IFN-α(treatment group)or IFN-α(control group).The therapeutic course for them was 6 months,and the changes of markers of liver function and fibrosis were observed and compared.Results:In therapy group, serum alanine aminotransferase decreases to normal range in 80.77% of the patients which were significantly different from those of control group (P<0.05).Levels of serum hyaluronidase(HA),laminin(LN),pro-collegen typeⅢ(PC-Ⅲ) and collegenⅣ(Ⅳ-C) were significantly different between the two groups(P<0.05 or P<0.01).Conclusion:IFN-αcombined with oxymatrine shows the better effect in improving liver function and preventing hepatic fibrosis than that in using IFN-αalone.